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ABSTRACT
Introduction: Fibromyalgia syndrome (FM) is
characterized by persistent pain which is often
refractory to common analgesic therapies and is
particularly disabling. The objective of this
study was to evaluate the therapeutic efficacy
of duloxetine (DLX) ? pregabalin (PGB) in
patients suffering from FM and the possible
added benefit of the lipid signaling molecule,
palmitoylethanolamide (PEA). PEA is
well-documented to exert anti-inflammatory,
analgesic, and pain-relieving effects at both the
preclinical and clinical level.
Methods: A total of 80 patients were recruited in
two steps. The first was a retrospective
observational study comprising 45 patients.
This patient group received DLX ? PGB for
6 months. The second step was a prospective
observational study with 35 patients. Patients in
this cohort began treatment with DLX ? PGB at
the same dosage as for the retrospective study
plus micronized PEA (PEA-m; Epitech Group,
Italy) and ultramicronized PEA (PEA-um;
Epitech Group, Italy) for 3 months. Positive
tender points (TPs), pain evoked, and pain
intensity were evaluated at baseline and after 3
and 6months in both studies. Statistical analyses
were employed for comparisonof datawithin the
two studies and between them.
Results: The retrospective observational study
(DLX ? PGB), after 3 months of treatment
showed a decrease of positive TPs, pain evoked,
and pain intensity. After 6 months of treatment,
these parameters had further improvement. In
the prospective observational study
(DLX ? PGB ? PEA), PEA introduction after
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3 months of therapeutic regimen with DLX ?
PGB provided a significant improvement in pain
symptoms, with a further reduction in the
number of TPs and significant reduction in
pain, compared to combined DLX ? PGB only
(p\0.0001 for TPs and Visual Analog Scale
comparisons). None of the patients experienced
adverse side effects.
Conclusion: Our study confirms the efficacy of
DLX ? PGB and demonstrates as well the added
benefit and safety of PEA in the treatment of
pain in patients affected by FM.
Keywords: Chronic pain; Duloxetine;
Fibromyalgia; Multimodal therapy; Pain;
Palmitoylethanolamide; Pregabalin
INTRODUCTION
Fibromyalgia syndrome (FM) is a very prevalent
rheumatic disease. Widely underestimated and
rarely diagnosed, it strikes between 2 and 4% of
the general population [1], with a clear
predominance in females. In Italy, disease
prevalence is 4.1% in the general population
(6.9% inwomen and 0.3% inmen) [1]. FM shows
a bimodal pattern of incidence: a first peak
between 25 and 35 years and a second between
45 and 55 years [2]. This syndrome is
characterized by widespread chronic pain,
tenderness in muscles and deep tissues, and
fatigue accompanied by other non-specific
symptoms, including sleep disturbances. In
particular, the widespread pain of FM is a
disabling condition and can become quite
marked when evoked by digital pressure at
tender points (TPs). Research suggests that pain
in FM syndrome is associated with a generalized
alteration in the central somatosensory system
[3, 4]. Central sensitization is likely sustained by
neuroinflammatory processes triggered by
microglia activation [5]. These data suggest that
the cross-talk between nervous and immune
systems plays a fundamental role in the onset
and progression of chronic pain in patients with
FM [6].
Diagnosis is still carried out according to
criteria developed in 1990 by the American
College of Rheumatology (ACR-90 criteria): a
history of widespread musculoskeletal pain
lasting at least 3 months and the presence of
at least 11 of 18 predefined TPs [7].
Nevertheless, the criteria of the ACR for FM of
2010 are increasingly applied [8], consisting of 2
scales: the Widespread Pain Index (WPI) and the
Symptom Severity (SS) scale. Numerous other
symptoms accompany the clinical course and
daily life of patients with FM: asthenia and
decreased muscle strength [9], headache,
irritable bowel syndrome, paresthesias, cramps
and fasciculations, cognitive disorders,
anxiety-depressive syndrome, blurred vision,
and unusual thermal, tactile, auditory, visual
and/or olfactory sensations [10, 11]. Although
trigger conditions such as strong
psycho-physical stress [12, 13] or febrile illness
(often of viral origin) have been suggested, the
pathogenesis of FM remains largely unknown.
Several hypotheses have been advanced, which
have led to the definition of FM as a
neuroimmune-endocrine disorder, whereby
the molecular mechanisms of neurotransmitter
dysfunction are associated with more obvious
neurological deficits [10, 14–20].
The etiopathogenic and clinical complexity
of FM requires a multidisciplinary approach
based on multimodal therapeutic strategies that
include also non-pharmacological
interventions [10, 14]. In particular: reduce
peripheral nociceptive input (muscle relaxants,
anti-inflammatory agents, physical therapy);
reduce or prevent central sensitization; treat
co-morbid conditions that contribute to
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maintaining a high pain threshold [17]. At
present, treatment of FM favors the use of
centrally acting anti-epileptics and
antidepressants, since drugs acting peripherally
(e.g., corticosteroids, non-steroidal
anti-inflammatory drugs) would be less
effective [21]. Anti-epileptics such as
gabapentin and pregabalin (PGB) have been
used in FM with especially encouraging results:
30% reduction in pain intensity in about half of
patients and 50% in about one-third [22].
Further, PGB was effective in persistent pain
refractory to common analgesics and sleep
disorders [23]. Antidepressants, by improving
the quality–quantity of sleep, can decrease some
associated symptoms such as fatigue and
gastrointestinal disorders, thereby contributing
to the optimization of analgesia in patients with
FM [24]. Among antidepressants, inhibitors of
serotonin/norepinephrine reuptake (e.g.,
duloxetine [DLX]) were more efficacious than
serotonin reuptake inhibitors [25, 26]. Optimal
results were achieved by integrating treatments
to take advantage of potential drug synergism
while assuring a better safety profile, owing to
the use of each drug at its lowest effective dose
[27].
An important advance in the field of
analgesic treatment for many chronic painful
conditions is represented by N-(2-hydroxyethyl)
esadecanamide (palmitoylethanolamide or PEA)
[28], a member of the naturally occurring family
of fatty acid amides. While initially recognized
for its anti-inflammatory activity, PEA is today
viewed as a key element of the body’s
endogenous mechanism to maintain/restore
homeostatic balance in the face of different
types of damage, including activation of the
inflammatory response and nociceptive
pathways. There is increasing evidence that
PEA acts as mediator of resolution of
inflammatory processes, thus counteracting
the progression of chronic inflammation: it is
synthesized/metabolized by microglia and mast
cells; it down-modulates mast cell and microglia
activation; and tissue levels of PEA are alterated
in brain areas involved in nociception following
neuropathic pain induction, as well as
conditions associated with injury to nervous
tissue (stroke, spinal cord injury) [29, 30]. The
mechanism of PEA action has been defined by
the acronym ALIA (Autacoid Local Injury
Antagonism) [31]. PEA is effective in the
treatment of chronic pain caused by different
etiopathogeneses [32] suggesting activation of
non-neuronal cells (mast cells and glia) as a
common factor in the various pathological
conditions [33–35]. Based on its effectiveness,
lack of drug interactions and absence of adverse
effects [30], PEA represents a promising and
innovative therapeutic strategy, especially if
placed within a multimodal pharmacotherapy.
The above findings encouraged us to
evaluate PEA effects in patients with FM. Our
investigation was devised so as to include two
separate studies: a retrospective observational
study and a prospective uncontrolled study. The
first was intended to assess efficacy and safety of
DLX ? PGB association in controlling patient
pain, while the second was to determine
whether micronized PEA (PEA-m; Epitech
Group, Italy) and ultramicronized PEA
(PEA-um; Epitech Group, Italy) would
provide additional clinical benefit over and
above to the results obtained with DLX ? PGB.
As compared to naı¨ve PEA (particle size profile
ranging between 100 and 700 lm), micronized
and ultramicronized PEA differs in their
particles size profile (2–10 lm and 0.8–6 lm at
most, respectively). Micronization and
ultramicronization processes yield a different
crystalline structure with higher energy content
and smaller particle size which result in better
diffusion and distribution of these molecules
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compared to the naı¨ve form, and thus superior
biological efficacy [30, 36]. The study aim was to
investigate, whether PEA-m and PEA-um would
provide additional clinical benefit in
controlling pain in patients with FM, in
multimodal therapy.
METHODS
The complete study was conducted on a total of
80 patients with FM, divided into two separate
arms, as described below. Patients were
recruited within the Medical Clinic at the
University of Perugia General Hospital ‘‘Santa
Maria’’ of Terni. All patients provided informed
written consent to participate. This study was
carried out in accordance with the Helsinki
Declaration of 1964, as revised in 2013, and
Good Clinical Practice and was approved by The
Local Ethical Committee of Umbria.
Retrospective Observational Study
Patients with a diagnosis of FM according to the
ACR criteria were selected in this step through
their clinical charts. All patients were referred to
the Ambulatory of Rheumatology outpatients
clinic of the Santa Maria General Hospital of
Terni and were treated with different
combination therapy (DLX ? PGB) for
6 months.
Prospective Uncontrolled Study
Patients with a diagnosis of FM according to the
ACR criteria were enrolled. PEA-um and PEA-m
were added at the third month of this existing
therapeutic regimen based on DLX ? PGB, for a
total duration of 3 months (PEA-um tablets
600 mg/bid in the first month, and PEA-m
tablets 300 mg/bid in the next 2 months).
Patients were selected based on their
superimposability in terms of number and
therapeutic doses to those enrolled in the
retrospective observational study.
In all patients, the main outcomes were TPs
and Visual Analog Scale (VAS). In both steps of
the study (retrospective and prospective), a
qualified rheumatologist performed the TP
examination in a standardized way. The
examiner used exactly the same instructions
for each subject and used a dolorimeter with a
pressure of 4 kg/cm2 to ensure equivalence in
application of pressure to the TPs. VAS, from
0 = no pain to 10 = the worst pain, was used to
measure pain score.
Statistical Analysis
A multivariate analysis generalized linear mixed
model (GLMM) was carried out to test whether
the clinical benefit of PEA was independent of
ongoing treatment with DLX ? PGB. Gender,
treatment, time, and interaction time
‘‘treatment’’ were used as covariate to test the




In this step, we analyzed 45 patients (37
women, 8 men; mean age 47 ± 5 years, range
40–52 years). At baseline, the patients showed
the following characteristics: number of
positive TPs equal to 14/18 with presence of
evoked pain in 3/3 and intensity of pain on the
VAS was equal to 6.9 ± 0.09. They received a
combination therapy comprising DLX ? PGB.
The mean daily dose of DLX was 39.3 mg/day
[30 mg/day (31 patients) and 60 mg/day (14
172 Pain Ther (2015) 4:169–178
patients)]; the mean daily dose of PGB was
47.2 mg/day [25 mg/day (15 patients),
50 mg/day (20 patients), and 75 mg/day (10
patients); Table 1]. After 3 months of therapy
with DLX ? PGB, the positive TPs decreased
from 14/18 to 8/18, the presence of evoked pain
diminished from 3/3 to 1/3, and the VAS scale
mean score went from 6.9 ± 0.09 to 4.0 ± 0.11.
After 6 months of therapy, evoked pain
remained at 1/3, positive TPs were further
reduced to 4/18, and the VAS scale mean score
reached the value of 3.0 ± 0.12.
Prospective Observational Study
The patient baseline characteristics were:
number of positive TPs equal to 14/18 with
presence of evoked pain in 3/3 and intensity of
Table 1 Clinical characteristics of the study populations






Mean ± SD 47 ± 5 48 ± 5
Range 40–52 42–53
VAS, mean ± SE
Baseline (ref.) 6.9 ± 0.09 6.6 ± 0.15
Third month 4.0 ± 0.11* 3.7 ± 0.17*
Sixth month 3.0 ± 0.12* 1.9 ± 0.17**
Positive TPs/18, mean ± SE
Baseline (ref.) 13.5 ± 0.33 13.8 ± 0.28
Third month 8.0 ± 0.17* 7.6 ± 0.19*
Sixth month 4.2 ± 0.18* 1.0 ± 0.14*
Therapy
DLX, mg/day (average) 39.3 36.0
PGB, mg/day (average) 47.2 49.2
PEA-m/PEA-um, mga – 600 bid (month 1)
300 bid (months 2–3)
bid Twice daily, DLX Duloxetine, PEA Palmitoylethanolamide, PGB Pregabalin; SD Standard deviation, SE Standard error,
TPs Tender points, VAS Visual analog scale
* p\0.05 vs previous evaluation, ** p\0.0001 vs previous evaluation
a Added at third month in the prospective study
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pain on the VAS scale equal to 6.6 ± 0.15. They
were treated with PGB ? DLX for three months;
the DLX mean dose was 36 mg/day [30 mg/day
(24 patients) and 60 mg/day (11 patients)]; the
PGB mean dose was 49.2 mg/day [25 mg/day
(12 patients), 50 mg/day (12 patients), and
75 mg/day (11 patients)]. At the third month
of this existing therapeutic regimen, PEA-um
and PEA-m were added for a total duration of
3 months (tablets 600 mg/bid in the first month
and tablets 300 mg/bid in the next 2 months;
Table 1). After 3 months of therapy with
DLX ? PGB ? PEA-um and PEA-m, the number
of positive TPs was 1/18 (Fig. 1), the evoked pain
was equal to 1/3 and the VAS scale mean score
diminished down from 3.7 ± 0.17 (month 3) to
1.9 ± 0.17 (month 6) (Fig. 2). The effects of the
combination therapy DLX ? PGB ? PEA-um
and PEA-m achieved significance (p\0.0001)
for VAS and TPs comparisons (Table 2). In the
analysis of variance, all included variables were
significant. The addition of PEA to the therapy
with DLX ? PGB provided a significant clinical
benefit independent of concomitant therapies
The VAS continually decreased over time; the
difference between treated and controls was
largest at month 6 (p\0.0001; Fig. 2). None of
the study patients discontinued therapy before
the end of the treatment period because they
did not experience either systemic/local adverse
events or intolerance to PEA.
DISCUSSION
One of the most noteworthy clinical features of
FM is widespread pain that, at particular points
Fig. 1 Reduction in number of positive tender points.
Retrospective group (circle with continuous line): patients
received DLX ? PGB from baseline to sixth month.
Number of TPS reduction was statistically signiﬁcant
*p\0.05. Prospective group (square with continuous line):
patients received DLX ? PGB from baseline to third
month. PEA-um/PEA-m was added to DLX ? PGB
(square with discontinuous line) from third to sixth month.
Number of TPS reduction was statistically signiﬁcant
**p\0.0001. DLX duloxetine, PEA-m micronized palmi-
toylethanolamide, PEA-m ultramicronized palmi-
toylethanolamide, PGB Pregabalin, TPs tender points
Fig. 2 Reduction in pain intensity by VAS measurement.
Retrospective group (circle with continuous line): patients
received DLX ? PGB from baseline to sixth month. VAS
reduction was statistically signiﬁcant *p\0.05. Prospective
group (square with continuous line): patients received
DLX ? PGB from baseline to third month. PEA-um/
PEA-m was added to DLX ? PGB (square with discon-
tinuous line) from third to sixth month. VAS reduction
was statistically signiﬁcant **p\0.0001. DLX duloxetine,
PEA-m micronized palmitoylethanolamide, PEA-m ultra-
micronized palmitoylethanolamide, PGB Pregabalin, VAS
Visual Analog Scale
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called TPs, can reach very high levels when
provoked by pressure [1]. Centrally acting
anti-epileptics and antidepressants have
proven beneficial in reducing pain intensity in
patients with FM, although their effects leave
much to be desired. Inflammation is a key
feature of chronic and neuropathic pain [33]. A
major advance in our understanding of the
pathogenic mechanisms underlying FM, as well
as other chronic pain syndromes with
important therapeutic consequences, is
knowledge about the physiological role played
by the body’s ‘built in’ mechanisms for
resolution of inflammation [34]. We are
coming to appreciate the importance of PEA as
an ‘on demand’ molecule produced to restore
homeostatic balance against stress and tissue
injury [34]. Initially studied for its
anti-inflammatory activity, PEA is now
considered to be at the center of these
endogenous mechanisms of protection. This
fatty acid amide down-modulates mast cell
degranulation and the consequent release of
pro-inflammatory mediators, as well as the
pro-algogenic actions of other immune-related
non-neuronal cells such as microglia—effects
likely to account for its pain-relieving qualities.
Indeed, several studies have demonstrated the
pain-relieving efficacy of PEA irrespective of
etiology, suggesting a common cellular
denominator in its mode of action [31, 32].
PEA anti-inflammatory and pain-relieving
properties have been amply demonstrated in a
number of animal models [30, 37, 38]. In
humans, PEA is highly efficacious in the
treatment of chronic pain associated with
different diseases [32, 39–42] and has no
deleterious side effects at pharmacologically
effective doses.
The main limitation of this exploratory
study is the open-label design without a
randomization and blinding. Therefore, it is
not possible to ascertain the extent to which
improvements with combination therapy may
have been due to patient or investigator
expectations. Moreover, it should be
considered that, when this study was
conducted, there were no available data on the
combination of PEA ? PGB on FM outcomes.
Therefore, this was designed as an exploratory
study to evaluate the potential effects of a
multimodal pharmacotherapy in FM. The
study results offer some clinical information
regarding the potential benefits of adding PEA
to DLX ? PGB in patients with FM, indicating
the need for further research into combinations
with different drug classes. Again, further
studies would need to be conducted to
evaluate the benefits of combining these
treatments in the general FM population.
Our research suggests the efficacy and safety
of PEA in the treatment of pain associated with
Table 2 Generalized linear mixed model analysis of tender points
Change between
DLX1 PGB group and
PEA 1 DLX 1 PGB
group
Standard error p value*
After 3 months 0.3461 0.2613 0.7705
After 6 months 3.1461 0.2458 \0.0001
DLX Duloxetine, PEA Palmitoylethanolamide, PGB Pregabalin
* Adjusted by Tukey–Kramer for multiple comparisons
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FM. Its introduction in the therapeutic regimen
of DLX ? PGB provided a significant
improvement in pain symptoms, with a
further reduction in the number of TPs and
significant reduction in pain, compared to
combined DLX ? PGB only. It is interesting to
note that the results achieved in 3 months with
PEA-um and PEA-m added to therapeutic
regimen are significantly better than those
after 6 months of DLX ? PGB only, and that
this improvement appeared to depend on PEA.
Given its effectiveness, lack of drug–drug
interactions, and absence of adverse events,
PEA-um and PEA-m may be a promising
therapeutic strategy for the treatment of FM
and other disorders with chronic pain,
especially if utilized in the context of a
multimodal pharmacotherapy.
CONCLUSIONS
The results from this open-label,
non-randomized, non-blinding clinical study
suggest that adding PEA to initial PGB ? DLX
therapy improved the outcome of FM. For some
patients requiring more than one FM
medication, the addition of PEA may be a
favorable treatment option. Again, further
studies would need to be conducted to
evaluate the benefits of combining these
treatments in the general FM population.
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